What is the current Price Target for the Lexeo Therapeutics stock?

The average Lexeo Therapeutics target price is $18.87. This is 96.36% higher than the current stock price. The highest price target is 227.78%, the lowest is 26.12%. 12 Analysts have issued a price target Lexeo Therapeutics 2027 .

How high will the Lexeo Therapeutics stock rise?

No reliable answer can be given as to how high the Lexeo Therapeutics stock will rise. The performance of stocks, including the Lexeo Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Lexeo Therapeutics stock today?

The performance of Lexeo Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Lexeo Therapeutics stock fall?

The decline in Lexeo Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Lexeo Therapeutics Forecast, price target & analysts

$9.61

3.22% day before yesterday

Nasdaq, Jan 02, 10:00 pm CET

ISIN

US52886X1072

Symbol

LXEO

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Lexeo Therapeutics Target price 2026 - Analyst rating & recommendation

Lexeo Therapeutics Classifications & Recommendation:

Buy

94%

Hold

Lexeo Therapeutics Price Target

Target Price	$18.87
Price	$9.61
Potential	96.36% register free of charge
Number of Estimates	12

	12 Analysts have issued a price target Lexeo Therapeutics 2027 . The average Lexeo Therapeutics target price is $18.87. This is 96.36% register free of charge higher than the current stock price. The highest price target is $31.50 227.78% register free of charge , the lowest is $12.12 26.12% register free of charge .
	A rating was issued by 16 analysts: 15 Analysts recommend Lexeo Therapeutics to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Lexeo Therapeutics stock has an average upside potential 2027 of 96.36% register free of charge . Most analysts recommend the Lexeo Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-3.06	-2.03
	13.75%	33.66%
P/E		negative

12 Analysts have issued a Lexeo Therapeutics forecast for earnings per share. The average Lexeo Therapeutics EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-3.06	13.75%
2025	$-2.03 33.66% Unlock
2026	$-1.61 20.69% Unlock
2027	$-1.73 7.45% Unlock
2028	$-1.23 28.90% Unlock
2029	$0.48 139.02% Unlock
2030	$1.36 183.33% Unlock
2031	$6.83 402.21% Unlock
2032	$11.96 75.11% Unlock

Current	-5.59	115.08%
2025	-4.74 15.16% Unlock
2026	-5.98 26.16% Unlock
2027	-5.56 7.02% Unlock
2028	-7.82 40.65% Unlock
2029	20.05 356.39% Unlock
2030	7.08 64.69% Unlock
2031	1.41 80.08% Unlock
2032	0.80 43.26% Unlock

Lexeo Therapeutics...

Current Lexeo Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Raymond James	Locked ➜ Locked	Locked	Dec 18 2025
Chardan Capital	Locked ➜ Locked	Locked	Dec 11 2025
Cantor Fitzgerald	Locked ➜ Locked	Locked	Dec 01 2025
Cantor Fitzgerald	Locked ➜ Locked	Locked	Nov 20 2025
Chardan Capital	Locked ➜ Locked	Locked	Nov 05 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 21 2025
Guggenheim	Locked ➜ Locked	Locked	Oct 15 2025

Analyst Rating	Date
Locked Raymond James: Locked ➜ Locked	Dec 18 2025
Locked Chardan Capital: Locked ➜ Locked	Dec 11 2025
Locked Cantor Fitzgerald: Locked ➜ Locked	Dec 01 2025
Locked Cantor Fitzgerald: Locked ➜ Locked	Nov 20 2025
Locked Chardan Capital: Locked ➜ Locked	Nov 05 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 21 2025
Locked Guggenheim: Locked ➜ Locked	Oct 15 2025

Discover more stocks with a high price target

Coinbase Global, Inc. 72.49%

BioNTech SE - ADR 47.69%

Netflix 47.13%

Adidas 40.14%

Rheinmetall 40.07%

Deutsche Telekom 39.32%

NIO ADR 38.91%

Microsoft 35.87%

Uber Technologies 35.41%

Amazon.com 35.10%

NVIDIA 35.03%

BYD 34.55%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now